{"organizations": [], "uuid": "9a2e5facf3fd0057fdad4047fe8980f4314877ae", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.morningstar.com", "main_image": "", "site_section": "http://news.morningstar.com/all/dow-jones/technology.aspx", "section_title": "News Archive: Technology", "url": "http://news.morningstar.com/all/dow-jones/technology/2015100610840/medicines-co-reaches-partnership-pact-with-japanese-drug-firm.aspx", "country": "US", "title": "Medicines Co. Reaches Partnership Pact With Japanese Drug Firm", "performance_score": 0, "site": "morningstar.com", "participants_count": 1, "title_full": "Medicines Co. Reaches Partnership Pact With Japanese Drug Firm", "spam_score": 0.0, "site_type": "news", "published": "2015-10-06T03:00:00.000+03:00", "replies_count": 0, "uuid": "9a2e5facf3fd0057fdad4047fe8980f4314877ae"}, "author": "morningstar.com", "url": "http://news.morningstar.com/all/dow-jones/technology/2015100610840/medicines-co-reaches-partnership-pact-with-japanese-drug-firm.aspx", "ord_in_thread": 0, "title": "Medicines Co. Reaches Partnership Pact With Japanese Drug Firm", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Medicines Co. reached a partnership deal with Tokyo-based SymBio Pharmaceuticals Ltd. that the president of the New Jersey company said provides potential for its first product to be marketed in Japan.\nMedicines shares rose 8.4% to $38.29 in recent after-hours trading.\nUnder the agreement, Medicines would grant an exclusive license to SymBio to develop and commercialize its Ionsys product for postsurgical pain, which received approval from the U.S. Food and Drug Administration in late April.\nMedicines President Glenn Sblendorio in prepared remarks on Tuesday said: \"This partnership further signals an important commitment of our company to pursue growth opportunities outside the United States through partnerships.\"\nUnder the agreement, Medicines will receive an upfront payment of $10 million and is eligible to receive certain regulatory and commercial milestone payments. Further specific financial details weren't provided.\nLast month, European regulators issued a positive opinion on Medicine's application for approval. In Japan, a phase I study for Ionsys targeting healthy Japanese patients has been completed.\nWrite to Tess Stynes at tess.stynes@wsj.com\n 06, 2015 18:45 ET (22:45 ", "external_links": ["http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif", "http://s7.addthis.com/static/btn/sm-share-en.gif", "http://www.addthis.com/bookmark.php?v=250", "http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Unchecked.gif"], "published": "2015-10-06T03:00:00.000+03:00", "crawled": "2015-10-08T02:48:21.880+03:00", "highlightTitle": ""}